SINTX Technologies issues revenue outlook and mid-year update

SINTX Technologies, Inc. (NASDAQ: SINT) issued a mid-year business update alongside its quarterly filing for the period ended June 30, 2026, outlining commercial progress, revenue guidance, and capital activity.

The Salt Lake City-based company projects total revenue of $900,000 to $1.1 million for the third quarter of 2026 and $1.0 million to $1.3 million for the fourth quarter, citing increased commercial activity and shipments tied to previously announced industrial purchase orders. The company cautioned that actual results could differ materially due to factors including customer schedule changes, manufacturing yield, and shipment timing.

During the first half of 2026, SINTX initiated a Limited Use Release of its FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System, which received 510(k) clearance in October 2025. The company established a network of 12 independent orthopedic distributors to support the rollout.

The company received approximately $3.2 million in new industrial ceramic purchase orders from contract manufacturing customers, with initial shipments commenced and revenue recognition expected to begin in the third quarter of 2026.

In the second quarter, SINTX completed financing transactions generating approximately $5.0 million in gross proceeds through a private placement and sales under its at-the-market facility. The company also received a 12-month extension from the National Institutes of Health to access approximately $745,000 remaining under the final phase of a $1.97 million NIH grant supporting spinal implant development.

SINTX completed construction of a 3D printing manufacturing facility intended for future production of patient-specific silicon nitride/PEEK orthopedic implants. Animal studies for antipathogenic suture and wound care technologies are scheduled to begin in the third quarter of 2026.

The company engaged Chris Lyons of Southern Metrics to evaluate inbound strategic partnership and licensing opportunities. H.C. Wainwright & Co. and Maxim Group initiated equity research coverage of SINTX with Buy ratings during the first half of 2026.

SINTX noted its forward-looking statements carry substantial uncertainty, including doubt regarding its ability to continue as a going concern without additional financing.

You May Also Be Interested In

• SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives
• Aardvark Therapeutics (AARD) Tops Q2 EPS by 21c
• Mount Logan Capital Inc. (MLCI) Reports Q2 Loss of $0.37